Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 430Neoplasms, Plasma Cell 58Recurrence 33Smoldering Multiple Myeloma 17Neoplasms 14Hematologic Diseases 11Immunoglobulin Light-chain Amyloidosis 8Leukemia, Plasma Cell 7Paraproteinemias 6Hematologic Neoplasms 6Amyloidosis 6Neoplasm, Residual 5Renal Insufficiency 4Plasmacytoma 4Lymphoma 4Disease Progression 4Disease 4Blood Protein Disorders 4Lymphoma, Non-Hodgkin 3POEMS Syndrome 2Lymphoproliferative Disorders 2Lymphoma, T-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Corneal Diseases 2Bone Marrow Neoplasms 2Wilms Tumor 1Vitamin D Deficiency 1Vascular Diseases 1

Interventions

Dexamethasone 6Lenalidomide 4Cyclophosphamide 4Melphalan 3daratumumab 2carfilzomib 2Prednisone 2ricolinostat 1pomalidomide 1deltacortene 1Transplantation, Autologous 1Thalidomide 1Calcium Dobesilate 1Bortezomib 1Bone Marrow Examination 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Disease × Lenalidomide × Plasma cell × Clear all
NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02215980 2024-07-22

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Fondazione EMN Italy Onlus

Phase 3 Completed
210 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT01160107 2023-06-29

RP_MPR

Fondazione EMN Italy Onlus

Phase 2 Completed
46 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡